KR101028952B1 - 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 - Google Patents

수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 Download PDF

Info

Publication number
KR101028952B1
KR101028952B1 KR1020107000942A KR20107000942A KR101028952B1 KR 101028952 B1 KR101028952 B1 KR 101028952B1 KR 1020107000942 A KR1020107000942 A KR 1020107000942A KR 20107000942 A KR20107000942 A KR 20107000942A KR 101028952 B1 KR101028952 B1 KR 101028952B1
Authority
KR
South Korea
Prior art keywords
alkyl
quinazoline
methyl
phenyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020107000942A
Other languages
English (en)
Korean (ko)
Other versions
KR20100018079A (ko
Inventor
엘리 월레스
조지 토팔로브
조셉 리시카토스
알렉산더 벅멜터
캉 챠오
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20100018079A publication Critical patent/KR20100018079A/ko
Application granted granted Critical
Publication of KR101028952B1 publication Critical patent/KR101028952B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020107000942A 2003-08-14 2004-08-10 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체 Expired - Lifetime KR101028952B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/642,440 2003-08-14
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US55171804P 2004-03-10 2004-03-10
US60/551,718 2004-03-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067003060A Division KR100953246B1 (ko) 2003-08-14 2004-08-10 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체

Publications (2)

Publication Number Publication Date
KR20100018079A KR20100018079A (ko) 2010-02-16
KR101028952B1 true KR101028952B1 (ko) 2011-04-12

Family

ID=34198338

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107000942A Expired - Lifetime KR101028952B1 (ko) 2003-08-14 2004-08-10 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
KR1020067003060A Expired - Lifetime KR100953246B1 (ko) 2003-08-14 2004-08-10 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067003060A Expired - Lifetime KR100953246B1 (ko) 2003-08-14 2004-08-10 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체

Country Status (23)

Country Link
US (2) US7452895B2 (enExample)
EP (1) EP1660090B1 (enExample)
JP (1) JP4828421B2 (enExample)
KR (2) KR101028952B1 (enExample)
CN (3) CN103772373B (enExample)
AR (1) AR045378A1 (enExample)
AU (1) AU2004264937B2 (enExample)
BR (1) BRPI0413565B8 (enExample)
CA (1) CA2535614C (enExample)
CL (1) CL2004002066A1 (enExample)
CY (1) CY1113992T1 (enExample)
DK (1) DK1660090T3 (enExample)
ES (1) ES2399427T3 (enExample)
IL (1) IL173593A (enExample)
IS (1) IS8288A (enExample)
MX (1) MXPA06001767A (enExample)
NO (1) NO336275B1 (enExample)
NZ (1) NZ545459A (enExample)
PL (1) PL1660090T3 (enExample)
PT (1) PT1660090E (enExample)
RU (1) RU2350605C2 (enExample)
TW (1) TWI353982B (enExample)
WO (1) WO2005016346A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR101086967B1 (ko) * 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
JP5944514B2 (ja) 2011-10-14 2016-07-05 アレイ バイオファーマ、インコーポレイテッド 固体分散体
NZ756264A (en) 2012-03-23 2022-09-30 Array Biopharma Inc Treatment of brain cancer
CN108135900A (zh) * 2015-09-04 2018-06-08 亚狮康私人有限公司 包含瓦尼替尼及抗癌剂之组合疗法
WO2017184086A1 (en) * 2016-04-21 2017-10-26 Aslan Pharmaceuticals Pte. Ltd. Method of treating liver cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
KR102845148B1 (ko) 2017-04-28 2025-08-20 씨젠 인크. Her2 양성 암의 치료
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
LT3853220T (lt) 2018-09-18 2024-03-12 F. Hoffmann-La Roche Ag Chinazolino dariniai kaip antinavikiniai preparatai
WO2020076239A1 (en) 2018-10-09 2020-04-16 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
IL309252A (en) 2021-06-26 2024-02-01 Array Biopharma Inc Inhibitors of HER2 mutations
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
KR20240167844A (ko) * 2022-03-28 2024-11-28 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용
TW202530231A (zh) * 2023-09-27 2025-08-01 大陸商江蘇恒瑞醫藥股份有限公司 喹唑啉衍生物的可藥用鹽、其結晶形式及用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990082583A (ko) * 1996-02-14 1999-11-25 돈 리사 로얄 항종양제인 퀴나졸린 유도체

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
NZ520093A (en) 1997-11-11 2004-03-26 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EP1131304B1 (en) 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
DK1553097T3 (da) * 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
CZ20021010A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
PT1257526E (pt) 2000-02-17 2005-09-30 Bristol Myers Squibb Co Ligandos derivados de anilina para o receptor de tiroide
TR200402656T4 (tr) 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
HUP0401646A2 (hu) 2001-11-03 2004-12-28 Astrazeneca Ab, Tumorellenes hatású kinazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP2006515871A (ja) 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
JP2007501854A (ja) 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
CA2536140A1 (en) 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
BRPI0416190A (pt) 2003-11-06 2007-01-23 Pfizer Prod Inc combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990082583A (ko) * 1996-02-14 1999-11-25 돈 리사 로얄 항종양제인 퀴나졸린 유도체

Also Published As

Publication number Publication date
CN103664802A (zh) 2014-03-26
JP2007502295A (ja) 2007-02-08
BRPI0413565B8 (pt) 2021-05-25
PT1660090E (pt) 2013-01-11
BRPI0413565A (pt) 2006-10-17
CN103664802B (zh) 2015-08-05
TWI353982B (en) 2011-12-11
CN103772373B (zh) 2017-06-09
CN102432552A (zh) 2012-05-02
KR20100018079A (ko) 2010-02-16
CN102432552B (zh) 2016-01-20
RU2350605C2 (ru) 2009-03-27
TW200519096A (en) 2005-06-16
RU2006103493A (ru) 2007-09-20
KR100953246B1 (ko) 2010-04-16
CN103772373A (zh) 2014-05-07
PL1660090T3 (pl) 2013-04-30
DK1660090T3 (da) 2012-12-17
NO336275B1 (no) 2015-07-06
US7452895B2 (en) 2008-11-18
AR045378A1 (es) 2005-10-26
AU2004264937B2 (en) 2010-04-29
MXPA06001767A (es) 2006-05-12
NZ545459A (en) 2009-12-24
IS8288A (is) 2006-02-07
IL173593A (en) 2011-11-30
EP1660090A4 (en) 2008-12-03
WO2005016346A1 (en) 2005-02-24
EP1660090B1 (en) 2012-11-21
EP1660090A1 (en) 2006-05-31
JP4828421B2 (ja) 2011-11-30
BRPI0413565B1 (pt) 2019-10-01
AU2004264937A1 (en) 2005-02-24
US8278314B2 (en) 2012-10-02
ES2399427T3 (es) 2013-04-01
US20050043334A1 (en) 2005-02-24
CY1113992T1 (el) 2016-07-27
CA2535614A1 (en) 2005-02-24
CL2004002066A1 (es) 2005-06-03
HK1085400A1 (en) 2006-08-25
CA2535614C (en) 2009-12-22
NO20061171L (no) 2006-04-10
IL173593A0 (en) 2006-07-05
US20090048279A1 (en) 2009-02-19
KR20060064630A (ko) 2006-06-13

Similar Documents

Publication Publication Date Title
KR101028952B1 (ko) 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US10780073B2 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP6791979B2 (ja) 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
US11174273B2 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
KR102526281B1 (ko) 옥사지노-퀴나졸린 및 옥사지노-퀴놀린형 화합물, 이의 제조방법 및 용도
TWI820414B (zh) 喹唑啉類化合物、製備方法及其應用
HK1085400B (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
HK1162929A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20100115

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100212

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100628

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110128

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110405

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110405

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140324

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140324

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160324

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160324

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170329

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170329

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180328

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180328

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200325

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20240320

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20250210

Termination category: Expiration of duration